Literature DB >> 18462185

Helicobacter pylori eradication therapy: indications, efficacy and safety.

Avelyn Kwok1, Thao Lam, Peter Katelaris, Rupert Wl Leong.   

Abstract

BACKGROUND: Helicobacter pylori infects up to half of the world's population. It remains the major cause of peptic ulcer disease and is recognised as a carcinogen for its role in gastric carcinogenesis. Successful eradication of the bacteria is associated with improved health outcomes including fewer dyspeptic symptoms, reduced peptic ulcer recurrence and rebleeding, reduced peptic ulcer risk with NSAIDs and as a cure for low-grade gastric MALT lymphoma. The risk of gastric cancer is reduced in those without premalignant mucosal abnormalities at the time of eradication.
OBJECTIVE: This review outlines the current indications and options for therapy of H. pylori with particular reference to drug-induced adverse events associated with treatment.
METHODS: The indications for H. pylori eradication are evidence-based and in accordance with recent consensus statements and recommendations. The eradication treatment is based on numerous clinical trials and meta-analyses. RESULTS/
CONCLUSION: Eradication therapy, in general, is safe and well tolerated. Antibiotic therapy may be associated with significant drug adverse reactions, especially gastrointestinal symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18462185     DOI: 10.1517/14740338.7.3.271

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  2 in total

1.  Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.

Authors:  Zaigham Abbas; Javed Yakoob; Shahab Abid; Wasim Jafri; Muhammad Islam; Zahid Azam; Imran Hilal
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

2.  Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study.

Authors:  Endalew Gebeyehu; Desalegn Nigatu; Ephrem Engidawork
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.